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Aims: Increased endothelin-1 (ET-1) is a hallmark of pulmonary arterial hypertension (PAH), and contributes to
its pathogenesis. The factors controlling ET-1 in PAH are poorly understood. Combinedwith other stimuli, vascu-
lar endothelial growth factor (VEGF) blockade results in PAH-like lesions in animal models, and has been associ-
ated with PAH in humans. The effects of VEGF on ET-1 production by human lung blood microvascular
endothelial cells (HMVEC-LBl) are unknown.
Main methods:We exposed HMVEC-LBl in-vitro to human VEGF-121 (40 ng/mL) in serum-free medium for 7 h,
in the absence or presence of the VEGF receptor antagonist, SU5416 (3 and 10 μM). ET-1 production was mea-
sured in the supernatant. Phosphorylation of VEGF receptor 2 (VEGFR2) was measured by Western blotting
after exposure to VEGF without or with SU5416 for 5 and 10 min.
Key ﬁndings: VEGF effectively caused VEGFR2 phosphorylation, which was blocked by SU5416. VEGF decreased
ET-1 production by at least 29%. In the absence of VEGF, SU5416 increased ET-1 production, by 16% at 10 μM,
and SU5416 was able to completely abolish the VEGF effect on ET-1 production.
Signiﬁcance: VEGFmay promote vascular health by decreasing ET-1 production in HVMEC-LBl. Blockade of VEGF
signaling by SU5416 increases ET-1 levels. The role of VEGF inmodulating endothelin production in PAHdeserves
further study.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The pathogenesis of pulmonary arterial hypertension (PAH) in-
volves microvascular endothelial proliferation and dysfunction,
with formation of plexiform lesions (Morrell et al., 2009; Tuder
et al., 2009). One manifestation of this dysfunction is increased pro-
duction of the deleterious vasoconstrictor and mitogen, endothelin-
1 (ET-1) (Giaid et al., 1993; Stewart et al., 1991). It has been proposed
that in PAH a variety of injurious stimuli result in endothelial apoptosis,
with emergence of apoptosis-resistant endothelial clones that narrow
the vascular lumen, restricting blood ﬂow and ultimately causing right
heart failure and death (Teichert-Kuliszewska et al., 2006; Tuder et al.,
2001a).
Vascular endothelial growth factor (VEGF) is important in endo-
thelial homeostasis, controlling differentiation, mitogenicity andneral Hospital, 3755 Cote Ste
14 340 7531; fax: +1 514 340
en).
. This is an open access article underendothelial survival (Ferrara, 2004). VEGF increases nitric oxide
and prostacyclin production. Loss of VEGF signaling results in endo-
thelial apoptosis. However, the role of VEGF in PAH is complex.
Levels of VEGF and its receptors are increased in PAH (Hirose et al.,
2000; Tuder et al., 2001a). Confounding the issue is the ﬁnding that
VEGF blockade in animals, combined with other stimuli such as hyp-
oxia, causes pulmonary hypertension and has provided a useful
model of PAH (Taraseviciene-Stewart et al., 2002; Tuder et al.,
2001b). Loss of VEGF might contribute to the endothelial apoptosis
that is thought to be an initiating event in PAH (Teichert-
Kuliszewska et al., 2006). Indeed, PAH has been reported in humans
after treatment with bevacizumab, a VEGF blocker (Liotta et al.,
2009). Thus, VEGF may play a role in the pathogenesis of PAH.
The stimuli for increased ET-1 in PAH are unknown. It is not known
how ET-1 synthesis by pulmonary microvascular endothelium is affect-
ed by VEGF. We therefore explored the effects of VEGF on ET-1 produc-
tion. The bone morphogenic protein (BMP) and transforming growth
factor-β (TGFβ) receptor pathways are highly involved in the develop-
ment of heritable PAH (Morrell et al., 2009). BMP-9 is a strong activator
of endothelial activin receptor-like kinase 1 (David et al., 2007). We
have previously demonstrated that BMP-9 stimulates ET-1 production
by lung microvascular endothelial cells in vitro (Star et al., 2010). Wethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1.Western blot showing levels of phosphorylated VEGF receptor-2 (P-VEGFR2), in
HMVEC-LBl in basal medium and after 5 and 10 minute exposure to VEGF (40 ng/mL).
The VEGF receptor blockers (E)-FeCP-oxindole and SU5416 were added in the indicated
lanes. GAPDH is used as a loading control.
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fects on ET-1 production.
Materials and methods
Cell cultures
Human microvascular endothelial cells of the lung-blood (HMVEC-
LBl, Lonza, Walkersville, MD) or human umbilical vein endothelial
cells (HUVEC, Lonza, Walkersville, MD) were plated into 24-well
plates and grown to conﬂuence in EGM-2MVmedium (Lonza) contain-
ing 2.5% fetal bovine serum (FBS) plus supplements. Only cells in pas-
sage 5 were used, with n = 12 wells per experimental condition.
Experimental design
To conﬁrm in HMVEC-LBl the appropriate signaling of VEGF via its
receptor, phosphorylation of the VEGF receptor 2 (VEGFR2) was
measured by Western blotting after exposure to VEGF-121 (0 or
40 ng/mL, Peprotech, Rocky Hill, NJ) in serum-free medium with
0.1% bovine serum albumin (BSA), with or without the VEGF recep-
tor antagonists, SU5416 (3 μM, CID 5329098, Cayman Chemical,
Ann Arbor, Michigan) or (E)-FeCP-oxindole (1 μM, CID 57369962,
Tocris, Minneapolis, MN ), for 5 and 10 min. The cells were then im-
mediately lysed in SDS sample buffer. The cell lysates were separated
on a polyacrylamide gel and then transferred to a PVDF membrane.
Afterwards, the samples were blocked in 5% fat free milk in TBST for 1
h. The membranes were subsequently incubated overnight at 4 °C in
TBST with 5% BSA containing antibodies to either rabbit anti-P-
VEGFR2 (Cell Signaling, Danvers, MA) or the housekeeping gene
mouse anti-GAPDH (Fitzgerald, Concord, MA). All membranes were
then washed in TBST and incubated with anti-rabbit (Cell Signaling,
Danvers, MA ) or anti-mouse (Abcam, Cambridge, UK) antibodies.
After a ﬁnal washing the membranes were incubated with Western
Lightning Plus-ECL (Perkin Elmer, Waltham, MA) and exposed to ﬁlm.
To study the effects on ET-1 production and to search for a dose
response, after conﬂuence of HMVEC-LBl or HUVEC, the medium
was replaced with medium containing VEGF-121 (0–40 ng/mL) in
serum-free medium for 7 h. The supernatants were collected at the
end of the study period, and frozen at −70 °C. To examine interac-
tions between VEGF and BMP9 with reference to ET-1 production,
the HMVEC-LBl and HUVEC were exposed to VEGF-121 (40 ng/mL)
and/or BMP9 (2.5 ng/mL, R&D Systems, Minneapolis, MN ) in serum-
free medium for 7 h. The supernatants were then collected and frozen
as above. In another experiment, HMVEC-LBl were exposed to VEGF-
121 (40 ng/mL) in serum-free medium for 7 h, with or without the
VEGF receptor antagonist SU5416 (0–10 μM). The supernatant was
collected and frozen. In all these experiments, the supernatant was
subsequently thawed and immunoreactive ET-1 levels were
measured by ELISA (Enzo Life Sciences, Ann Arbor, Michigan) and
expressed as pg/mL.
Statistics
Data are expressed as mean ± SD. To compare groups, analysis-
of-variance was performed and followed, where appropriate by the
Tukey–Kramer multiple comparison test.
Results
Effects of VEGF and its blockers on VEGF receptor phosphorylation (Fig. 1)
Using Western blotting, in the HMVEC-LBl and in serum-free
medium, there was no evidence of background VEGF receptor-2
phosphorylation. Addition of the VEGF receptor blockers, (E)-FeCP-
oxindole and SU5416, did not affect the background phosphorylation.Addition of VEGF caused rapid phosphorylation as detected after
5 min, and this was sustained although slightly diminished at 10 min.
Attempted blockade with (E)-FeCP-oxindole at the manufacturer's rec-
ommended dose had no effect on the phosphorylation. However,
SU5416 blocked the effects of VEGF, completely preventing VEGFR2
phosphorylation.
Effects of VEGF on ET-1 production (Fig. 2)
In both HMVEC-LBl and HUVEC, exposure to VEGF signiﬁcantly de-
creased ET-1 production, as assessed by ET-1 levels in the supernatant,
after 7 h. This reduction occurred in a concentration-dependent man-
ner, with the greatest effect in each case seen at VEGF 40 ng/mL. At
that concentration, ET-1 levels were decreased by 63% in HMVEC-LBl
and by 48% in HUVEC. Within the range studied, the dose response
was more evident in HMVEC-LBl.
Effects of VEGF receptor blockade on ET-1 production (Fig. 3)
In HMVEC-LBl not exposed to VEGF, and in serum-free medium,
addition of the VEGF receptor blocker, SU5416, signiﬁcantly in-
creased basal ET-1 production, by up to 21% at 3 ng/mL, p b 0.02. Ad-
dition of VEGF alone signiﬁcantly decreased ET-1 production by 29%
versus no VEGF, p b 0.02. In the presence of VEGF, addition of SU5416
completely blocked the inhibitory effects of VEGF on ET-1 produc-
tion, with an increase in ET-1 levels of 82% as compared to VEGF
alone. Furthermore, in the presence of SU5416, the ET-1 levels even
surpassed those of the baseline control (no VEGF) by 30%, p b 0.02.
At 3 ng/mL of SU5416, the ET-1 levels in the presence of VEGF were
also slightly higher than those with SU5416 (3 ng/mL) in the ab-
sence of VEGF, p b 0.02.
Effects of VEGF and BMP-9 on ET-1 production (Fig. 4)
In HMVEC-LBl, VEGF (40 ng/mL) signiﬁcantly reduced ET-1 produc-
tion by 29%. As has been previously described, addition of BMP-9
(2.5 ng/mL) greatly stimulated ET-1 production, by 81% over baseline.
Combination of VEGF and BMP-9 resulted in lower ET-1 levels as com-
pared to BMP-9 alone, but they were still 35% higher than baseline
and 90% higher than with VEGF alone. A similar pattern was observed
when HUVEC were studied.
Fig. 3. Effects of the VEGF receptor blocker SU5416 0 ng/mL (control, black bars), 3 ng/mL
(white bars) and 10 ng/mL (diagonal bars) on ET-1 levels in the supernatant of HMVEC-
LBl in the absence or presence of VEGF (40 ng/mL), after a 7 hour exposure. Bars are
mean + SD. *, p b 0.02 versus respective control; **, p b 0.02 versus other control; #,
p b 0.02 versus both controls and other 3 ng/mL group.
Fig. 4. Effects of VEGF (40 ng/mL) and BMP-9 (2.5 ng/mL) on ET-1 levels in the superna-
tant of HMVEC-LBl and HUVEC after a 7 hour exposure. Black bars are control, white bars
are VEGF alone, diagonal bars are BMP-9 alone and hatched bars are VEGF and BMP-9
combined. Bars are mean + SD. *, p b 0.02 versus respective control; **, p b 0.02 versus
all other respective groups for a given cell type.
Fig. 2. Effects of various concentrations of VEGF on ET-1 levels in the supernatant of
HMVEC-LBl (upper) and HUVEC (lower) after a 7 h exposure. Bars are mean + SD. *,
p b 0.02 versus no VEGF.
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The available data on VEGF and PAH might seem paradoxical, but
it is clear that VEGF and its absence are implicated in the life and
death of pulmonary microvascular endothelial cells in PAH, and in
endothelial dysfunction (Voelkel et al., 2002). Levels of both VEGF
and its receptor are increased in PAH, but it is unclear if they are pro-
tective, adaptive or a manifestation of cellular dysfunction (Geiger
et al., 2000; Hirose et al., 2000; Niimi et al., 2000; Tuder et al.,
2001a). VEGF therapy can attenuate pulmonary hypertension in an-
imal models (Farkas et al., 2009). Although VEGF is a potent survival
factor for endothelium, PAH is characterized by endothelial cell apo-
ptosis and emergence of apoptosis resistant clones (Voelkel et al.,
1998). Moreover, VEGF receptor blockade combined with other
stimuli such a hypoxia or shear stress, induces PAH-like lesions in
animals. VEGF receptor blockade by itself has been associated with
PAH in humans receiving it for cancer therapy (Ciuclan et al., 2011;
Liotta et al., 2009). Thus, whether VEGF levels in established PAH
support the remaining healthy endothelium, or are contributing to
the excessive aberrant endothelial proliferation, is unknown.
VEGF promotes the production of mediators that are beneﬁcial to
vascular health, including nitric oxide and prostacyclin (He et al.,
1999; Ku et al., 1993; Tsurumi et al., 1997). However, in patients
with PAH, levels of nitric oxide and prostacyclin are reduced, and
levels of the vasoconstrictor and vascular mitogen, ET-1, are in-
creased (Christman et al., 1992; Giaid and Saleh, 1995; Giaid et al.,
1993; Stewart et al., 1991; Tuder et al., 1999).We previously hypoth-
esized that pulmonary microvascular endothelial dysfunction leads
to increased ET-1 production in PAH and that this might be driven
in part by mediator effects or altered gene expression in the cells. In-
deed, knockdown of BMPR-2 in vitro, simulating heritable PAH, in-
creases ET-1 production by human lung microvascular endothelial
cells (Star et al., 2013). Likewise, exposure of the cells to BMP-9,which activates a BMPR2 and ALK-1 complex, increases ET-1 levels
(Star et al., 2010). Given the important effects of VEGF, potentially ben-
eﬁcial and detrimental, in PAH, we studied its effects on endothelin
production.
Because of phenotypic heterogeneity between systemic and pul-
monary endothelium, between macrovascular and microvascular
endothelium, and between human endothelium and that of other
animals, we performed all experiments using HMVEC-LBl, endotheli-
al cells derived from human pulmonary microvasculature and there-
fore the cells most relevant to PAH. We ﬁrst demonstrated that the
cells had type 2 VEGF receptors that could be rapidly phosphorylated
by exposure to VEGF. We demonstrated that the VEGF receptor an-
tagonist SU5416 completely prevented this phosphorylation. We
also tested (E)-FeCp-oxindole, which is purported to block VEGFR2
(Spencer et al., 2011), but it was ineffective at preventing VEGF-
induced VEGFR2 phosphorylation, at doses well above the IC50 sug-
gested by the manufacturer. Thus, in subsequent experiments only
SU5416 was used. We cannot explain the lack of effect of (E)-FeCp-
oxindole other than to say that it was consistent in our model.
We found that VEGF decreased ET-1 production by HMVEC-LBL,
in a dose-dependent fashion. Although the effectiveness of VEGF varied
between experiments, it consistently had an inhibitory effect. We also
studied HUVEC and found a similar pattern, although the dose response
194 G.P. Star et al. / Life Sciences 118 (2014) 191–194wasmore evidentwithHMVEC-LBl. Our ﬁndingof an inhibitory effect of
VEGF on ET-1 production by HUVEC differs from a previous study using
HUVEC, where VEGF165, up to a dose of 10 ng/mL increased ET-1 pro-
duction (Lee et al., 2007). There may be differences between VEGF
121 and VEGF 165 that are as yet untested, or the culture conditions
may have been different. In another study, using bovine aortic endothe-
lial cells, VEGF increased ET-1 secretion in vitro (Matsuura et al., 1998).
We believe that we were seeing a VEGF-speciﬁc effect in reducing ET-1
production by the HMVEC-LBl cells because addition of SU5416
completely blocked the VEGF-induced decrease in ET-1. Moreover,
SU5416 in the presence of VEGF increased ET-1 production to levels
that exceeded the baseline control. In support of our ﬁndings, SU5416
increased circulating ET-1 levels in a structurally relevant murine
model of PAH (Ciuclan et al., 2011).
We previously showed that BMP-9 stimulates ET-1 production by
HMVEC-LBl (Star et al., 2010). This result was reproduced in the present
study. However, in both HMVEC-LBl and HUVEC, VEGF was able to re-
duce the BMP-9-induced stimulation of ET-1 production to a degree
similar to its ability to decrease ET-1 production in cells not stimulated
by BMP-9. Nevertheless, the ET-1 levels were never reduced by BMP-9
back to control levels of ET-1. An interaction between VEGF and ALK-1
has been described, and might provide a mechanism whereby VEGF
competes against BMP-9 for ALK-1 binding (Hu-Lowe et al., 2011). In
PAH, the endothelial cells are subjected to a multitude of mediators.
Our result with BMP-9 suggests that in PAH, where VEGF levels are
high and might inhibit ET-1 production, other cell signaling activators
such as BMPs might overcome the inhibition and result in high levels
of ET-1. Further study is needed in this area.
Conclusion
VEGF reduces ET-1 production by HMVEC-LBl in vitro. This can be
overcome by VEGF receptor blockade and by BMP-9, which interacts
with BMPR2 and ALK-1. These are observational studies. The role of
VEGF in modulating ET-1 levels in PAH, and the underlying mecha-
nisms, deserve further study.
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